[go: up one dir, main page]

EE05556B1 - 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks - Google Patents

3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks

Info

Publication number
EE05556B1
EE05556B1 EEP200100405A EEP200100405A EE05556B1 EE 05556 B1 EE05556 B1 EE 05556B1 EE P200100405 A EEP200100405 A EE P200100405A EE P200100405 A EEP200100405 A EE P200100405A EE 05556 B1 EE05556 B1 EE 05556B1
Authority
EE
Estonia
Prior art keywords
medicament
hydroxy
preparation
treatment
reductase inhibitor
Prior art date
Application number
EEP200100405A
Other languages
English (en)
Inventor
Eugene Cameron Norman
Anne Cotter Mary
Original Assignee
Astrazeneca Ab
The University Court Of The University Of Aberdeen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9902594.2A external-priority patent/GB9902594D0/en
Priority claimed from GBGB9902591.8A external-priority patent/GB9902591D0/en
Application filed by Astrazeneca Ab, The University Court Of The University Of Aberdeen filed Critical Astrazeneca Ab
Priority to EEP201200015A priority Critical patent/EE05621B1/et
Publication of EE200100405A publication Critical patent/EE200100405A/et
Publication of EE05556B1 publication Critical patent/EE05556B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200100405A 1999-02-06 2000-02-01 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks EE05556B1 (et)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EEP201200015A EE05621B1 (et) 1999-02-06 2000-02-01 Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902594.2A GB9902594D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
GBGB9902591.8A GB9902591D0 (en) 1999-02-06 1999-02-06 Pharmaceutical compositions
PCT/GB2000/000280 WO2000045818A1 (en) 1999-02-06 2000-02-01 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy

Publications (2)

Publication Number Publication Date
EE200100405A EE200100405A (et) 2002-10-15
EE05556B1 true EE05556B1 (et) 2012-08-15

Family

ID=26315085

Family Applications (2)

Application Number Title Priority Date Filing Date
EEP200100405A EE05556B1 (et) 1999-02-06 2000-02-01 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks
EEP201200015A EE05621B1 (et) 1999-02-06 2000-02-01 Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet

Family Applications After (1)

Application Number Title Priority Date Filing Date
EEP201200015A EE05621B1 (et) 1999-02-06 2000-02-01 Kombineeritud kompositsioonid, mis sisaldavad (E)-7-[4-(4-fluorofenl)-6-isopropl-2-[metl(metlsulfonl)amino]primidiin-5-l]-(3R,5S)-3,5-dihdrokshept-6-eenhapet

Country Status (33)

Country Link
US (4) US6894058B1 (et)
EP (2) EP1150678B1 (et)
JP (3) JP2002536332A (et)
KR (1) KR100699757B1 (et)
CN (1) CN1196488C (et)
AR (1) AR025512A1 (et)
AT (2) ATE485823T1 (et)
AU (1) AU763970B2 (et)
BR (1) BR0007996A (et)
CA (1) CA2368186C (et)
CY (2) CY1106879T1 (et)
CZ (2) CZ302881B6 (et)
DE (2) DE60045168D1 (et)
DK (2) DK1150678T3 (et)
EE (2) EE05556B1 (et)
ES (2) ES2286995T3 (et)
GB (1) GB0001662D0 (et)
HU (1) HU227642B1 (et)
IL (3) IL144730A0 (et)
IS (2) IS2793B (et)
MX (1) MXPA01007821A (et)
MY (1) MY138289A (et)
NO (1) NO330400B1 (et)
NZ (3) NZ513061A (et)
PL (1) PL198098B1 (et)
PT (2) PT1150678E (et)
RU (1) RU2239456C2 (et)
SI (2) SI1150678T1 (et)
SK (2) SK287792B6 (et)
TR (1) TR200102229T2 (et)
TW (1) TWI230067B (et)
WO (1) WO2000045818A1 (et)
ZA (1) ZA200105885B (et)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6555540B1 (en) * 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
RU2276997C2 (ru) 1999-08-30 2006-05-27 Санофи-Авентис Дойчланд Гмбх Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
DE10025308A1 (de) * 2000-05-23 2001-11-29 Bayer Ag Kombination von Cerivastatin mit ACE Inhibitoren und ihre Verwendung in Arzneimitteln
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
AR030379A1 (es) * 2000-08-22 2003-08-20 Novartis Ag Combinaciones
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
PL361097A1 (en) * 2000-10-12 2004-09-20 Nissan Chemical Industries, Ltd. Preventives and remedies for complications of diabetes
CA2426592A1 (en) * 2000-10-18 2002-04-25 Pfizer Products Inc. Combination of statins and sorbitol dehydrogenase inhibitors
CN1477976A (zh) * 2000-11-30 2004-02-25 �Ʒ� Gaba激动剂与醛糖还原酶抑制剂的组合
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
AU2003209851A1 (en) * 2002-03-20 2003-09-29 The University Of Queensland Method of treatment and/or prophylaxis
TW200810743A (en) * 2002-03-22 2008-03-01 Novartis Ag Combination of organic compounds
JP4395633B2 (ja) * 2002-08-29 2010-01-13 学校法人鈴鹿医療科学大学 非神経細胞の神経細胞への分化成熟法、該組成物と該組成物探索法
US7179941B2 (en) 2003-01-23 2007-02-20 Sanofi-Aventis Deutschland Gmbh Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
DE10302452B4 (de) * 2003-01-23 2005-02-24 Aventis Pharma Deutschland Gmbh Carbonylamino-substituierte Acyl-phenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
US9345671B2 (en) 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
WO2004096276A1 (ja) * 2003-04-28 2004-11-11 Sankyo Company, Limited 糖取り込み能増強剤
ATE526023T1 (de) * 2003-06-20 2011-10-15 Nephrogenex Inc Pyridoxamin zur verwendung in der behandlung von diabetischer nephropathie bei typ ii diabetes
US20090082407A1 (en) * 2004-06-18 2009-03-26 Biostratum, Inc. Pyridoxamine for the Treatment of Diabetic Kidney Disease
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
WO2005023766A1 (en) * 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005033067A1 (en) * 2003-10-07 2005-04-14 Biocon Limited SALT OF 1,2,6,7,8,8A-HEXAHYDRO-β,δ,6-TRIHYDROXY-2-METHYL-8-[(2S)-2-METHYL-1-OXOBUTOXY]-, (βR,δ R,1S,2S,6S,8S,8AR)- 1-NAPHTHALENEHEPTANOIC ACID WITH N,N-DIMETHYL-IMIDODICARBONIMIDIC DIAMIDE
KR100715114B1 (ko) * 2005-02-19 2007-05-10 한국유나이티드제약 주식회사 당뇨병 치료를 위한 약학적 조성물
CN101632673B (zh) * 2008-07-24 2011-08-10 鲁南制药集团股份有限公司 含有氯沙坦、吡格列酮和瑞舒伐他汀的药物组合物及其新用途
PL2326632T3 (pl) 2008-09-06 2017-10-31 Bionevia Pharmaceuticals Inc Nowy kokryształ choliny i epalrestatu
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
WO2013072770A2 (en) 2011-11-15 2013-05-23 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
WO2015053589A1 (ko) * 2013-10-11 2015-04-16 가톨릭대학교 산학협력단 메트포민 및 스타틴의 복합제를 이용한 자가면역질환의 예방 또는 치료용 조성물
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110747206B (zh) * 2019-11-05 2021-11-23 昆明理工大学 3-羟基-3-甲基戊二酸单酰辅酶a还原酶基因rkhmgr及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5190970A (en) 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DK0636027T3 (da) 1992-04-13 2000-01-31 Zeneca Ltd Angiotensin-II-antogonister mod sygdomme forbundet med forringet neuronal ledningshastighed, især diabetisk neuropati
GB9208116D0 (en) * 1992-04-13 1992-05-27 Ici Plc Therapeutic agents
AU1095695A (en) 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
WO1995026188A1 (en) 1994-03-29 1995-10-05 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2175385T5 (es) 1996-04-05 2006-06-01 Takeda Chemical Industries, Ltd. Combinacion farmaceutica que contiene un compuesto que tiene actividad antagonista de angiotensina ii y un compuesto que aumenta la sensibilidad a la insulina.
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
US6262076B1 (en) * 2000-01-28 2001-07-17 Ajinomoto Co., Inc. Pharmaceutical composition for use in the treatment of diabetic neuropathy
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment

Also Published As

Publication number Publication date
NZ513061A (en) 2003-06-30
EE200100405A (et) 2002-10-15
HUP0105138A2 (hu) 2002-04-29
MY138289A (en) 2009-05-29
ES2352803T3 (es) 2011-02-23
TWI230067B (en) 2005-04-01
NO330400B1 (no) 2011-04-04
JP2002536332A (ja) 2002-10-29
PT1897546E (pt) 2010-12-15
IL208330A0 (en) 2010-12-30
JP2014065718A (ja) 2014-04-17
NO20013812L (no) 2001-10-02
BR0007996A (pt) 2001-10-30
HK1118209A1 (en) 2009-02-06
JP2012051898A (ja) 2012-03-15
CY1106879T1 (el) 2012-05-23
DK1897546T3 (da) 2011-01-17
DE60035575D1 (de) 2007-08-30
CZ302881B6 (cs) 2012-01-04
MXPA01007821A (es) 2004-08-19
KR20010089635A (ko) 2001-10-06
PT1150678E (pt) 2007-09-14
EP1150678A1 (en) 2001-11-07
DK1150678T3 (da) 2007-10-08
CY1110992T1 (el) 2015-06-11
ES2286995T3 (es) 2007-12-16
CZ302893B6 (cs) 2012-01-11
IL144730A0 (en) 2002-06-30
EP1897546A1 (en) 2008-03-12
IS2820B (is) 2012-12-15
AU763970B2 (en) 2003-08-07
CN1338937A (zh) 2002-03-06
NZ536433A (en) 2006-08-31
DE60045168D1 (de) 2010-12-09
HUP0105138A3 (en) 2002-11-28
TR200102229T2 (tr) 2001-12-21
SK286854B6 (sk) 2009-06-05
SI1897546T1 (sl) 2011-02-28
IS6016A (is) 2001-07-20
EP1150678B1 (en) 2007-07-18
WO2000045818A1 (en) 2000-08-10
CZ20012806A3 (cs) 2002-02-13
AU2304700A (en) 2000-08-25
KR100699757B1 (ko) 2007-03-27
AR025512A1 (es) 2002-12-04
GB0001662D0 (en) 2000-03-15
IS2793B (is) 2012-08-15
US20120041010A1 (en) 2012-02-16
IS8978A (is) 2011-08-23
NZ525419A (en) 2004-12-24
NO20013812D0 (no) 2001-08-03
US20090186908A1 (en) 2009-07-23
RU2239456C2 (ru) 2004-11-10
CA2368186A1 (en) 2000-08-10
EE201200015A (et) 2012-10-15
PL350312A1 (en) 2002-12-02
ATE485823T1 (de) 2010-11-15
SK11102001A3 (sk) 2002-05-09
ATE367162T1 (de) 2007-08-15
SK287792B6 (sk) 2011-10-04
HU227642B1 (en) 2011-10-28
IL144730A (en) 2010-12-30
US6894058B1 (en) 2005-05-17
HK1041223A1 (en) 2002-07-05
US20050209128A1 (en) 2005-09-22
ZA200105885B (en) 2002-10-17
DE60035575T2 (de) 2008-04-03
SI1150678T1 (sl) 2008-02-29
CA2368186C (en) 2008-06-03
CN1196488C (zh) 2005-04-13
EE05621B1 (et) 2013-02-15
EP1897546B1 (en) 2010-10-27
PL198098B1 (pl) 2008-05-30

Similar Documents

Publication Publication Date Title
EE200100405A (et) 3-hüdroksü-3-metüülglutarüüli koensüümi kasutamine reduktaasi inhibiitorina ravimi valmistamiseks diabeetilise neuropaatia raviks
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
ZA200502496B (en) Ester compound and medicinal use thereof.
DE60037479D1 (de) Absorbierender Wegwerfartikel
DE60040308D1 (de) Absorbierender Wegwerfartikel
DE60012111D1 (de) Absorbierender Wegwerfartikel
BR0001826B1 (pt) fralda descartÁvel.
DE60044056D1 (de) Ristika eines organismus
ATE320436T1 (de) Dimere pyrrolobenzodiazepine
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
ZA200107450B (en) Dimeric compounds and their use as inhibitors of neuraminidase.
DE60324099D1 (de) Arzneistoffhaltiger tampon
DE60019848D1 (de) Absorbierender Wegwerfartikel
DE60015871D1 (de) Wegwerfhöschen
NO20020873L (no) Omfestbar absorberende artikkel
FR2846082B1 (fr) Corps actif electromagnetique non mortel
BR0000706B1 (pt) fralda descartÁvel.
BR0001216B1 (pt) fralda descartÁvel.
AU2002330850A1 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
EP1451183A4 (en) DIMERE COMPOUNDS AND THEIR USE AS ANTIVIRAL AGENTS
BR0004412B1 (pt) fralda descartÁvel.
AR027958A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades vasculares, que comprende propionil l-carnitina y coenzima q10
ZA200205415B (en) Novel therapeutic use of enoxaparin.
ITMI20001288A0 (it) Composti ad attivita' anti-hsv
TW583920U (en) Novel structure of shoes for farm use

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20140201